Avid Bioservices, Inc.
CDMO
NASDAQ
| Weiss Ratings | CDMO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | CDMO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Fair | |||
| Total Return Index | Fair | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | CDMO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.59 | |||
| Price History | CDMO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -- | |||
| 30-Day Total Return | -- | |||
| 60-Day Total Return | -- | |||
| 90-Day Total Return | -- | |||
| Year to Date Total Return | -- | |||
| 1-Year Total Return | -- | |||
| 2-Year Total Return | -- | |||
| 3-Year Total Return | -- | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -- | |||
| 52-Week Low % Change | -- | |||
| Price | CDMO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $12.51 | |||
| 52-Week Low Price | $5.90 | |||
| 52-Week Low Price (Date) | Mar 07, 2024 | |||
| 52-Week High Price (Date) | Feb 04, 2025 | |||
| Valuation | CDMO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | -- | |||
| Enterprise Value | 970.81M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -2.40 | |||
| Earnings Per Share Growth | -- | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 5.30 | |||
| Price/Book (Q) | 17.83 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | -- | |||
| Enterprise Value/EBITDA (TTM) | -- | |||
| Enterprise Value/EBIT | -- | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | CDMO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 63.84M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | CDMO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 714 508 6100 | |||
| Address | 14191 Myford Road Tustin, CA 92780 | |||
| Website | www.avidbio.com | |||
| Country | United States | |||
| Year Founded | 1981 | |||
| Profitability | CDMO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -13.54% | |||
| Profit Margin | -101.06% | |||
| Management Effectiveness | CDMO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -3.27% | |||
| Return on Equity | -- | |||
| Income Statement | CDMO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 150.45M | |||
| Total Revenue (TTM) | 150.45M | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | 11.55M | |||
| EBITDA (TTM) | -7.91M | |||
| EBIT (TTM) | -20.38M | |||
| Net Income (TTM) | -152.05M | |||
| Net Income Avl. to Common (TTM) | -152.05M | |||
| Total Revenue Growth (Q YOY) | 31.84% | |||
| Earnings Growth (Q YOY) | -82.82% | |||
| EPS Diluted (TTM) | -2.40 | |||
| EPS Diluted Growth (Q YOY) | -80.84% | |||
| Balance Sheet | CDMO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 35.12M | |||
| Cash Per Share (Q) | $0.55 | |||
| Total Current Assets (Q) | 96.51M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 44.81M | |||
| Current Ratio (Q) | 1.301 | |||
| Book Value Per Share (Q) | $0.70 | |||
| Total Assets (Q) | 323.48M | |||
| Total Current Liabilities (Q) | 74.16M | |||
| Total Debt (Q) | 207.02M | |||
| Total Liabilities (Q) | 278.67M | |||
| Total Common Equity (Q) | 44.81M | |||
| Cash Flow | CDMO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -14.94M | |||
| Cash from Financing (TTM) | 11.67M | |||
| Net Change in Cash (TTM) | 1.99M | |||
| Levered Free Cash Flow (TTM) | -806.90K | |||
| Cash from Operations (TTM) | 5.26M | |||
